ALNYLAM PHARMACEUTICALS, INC. Operating Lease Right-of-Use Assets
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Operating Lease Right-of-Use Assets of $183.36 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-07-30
- 2026-06-30: Operating Lease, Right-of-Use Asset $183.36M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $194.92M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $191.39M.
- 2025-06-30: Operating Lease, Right-of-Use Asset $192.40M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $183.36M 10-Q · filed 2026-07-30 |
| 2025-12-31 | $194.92M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $191.39M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $192.40M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $197.23M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $191.15M 10-K · filed 2026-02-12 |
| 2024-09-30 | $196.41M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $198.30M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $195.47M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $199.73M 10-K · filed 2025-02-13 |
| 2023-09-30 | $203.49M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $208.80M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $215.05M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $215.14M 10-K · filed 2024-02-15 |
| 2022-09-30 | $218.80M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $223.92M 10-Q · filed 2022-07-28 |
| 2022-03-31 | $228.77M 10-Q · filed 2022-04-28 |
| 2021-12-31 | $231.68M 10-K · filed 2023-02-23 |
| 2021-09-30 | $235.85M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $238.09M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $237.21M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $241.49M 10-K · filed 2022-02-10 |
| 2020-09-30 | $245.23M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $229.67M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $221.28M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $221.20M 10-K · filed 2021-02-11 |
| 2019-09-30 | $223.44M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $226.36M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $226.41M 10-Q · filed 2019-05-02 |
| 2019-01-01 | $230.00M 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |